Stocks · Health care · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX Clue Score43
United States Fiscal year ends December CIK 0001817713 Results filed 5 Nov 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
David Alan Campbell
7 Jan 2025
President and CEO
Sold on a plan
5,000
$60.00
$300.00K
David Alan Campbell
24 Dec 2024
President and CEO
Sold on a plan
25,000
$56.19
$1.40M
David Alan Campbell
3 Dec 2024
President and CEO
Sold on a plan
15,000
$67.00
$1.01M
David Alan Campbell
25 Nov 2024
President and CEO
Sold on a plan
6,719
$52.04
$349.65K
David Alan Campbell
25 Nov 2024
President and CEO
Sold on a plan
18,281
$51.43
$940.23K
David Alan Campbell
28 Oct 2024
President and CEO
Sold on a plan
11,103
$53.94
$598.91K
David Alan Campbell
28 Oct 2024
President and CEO
Sold on a plan
13,897
$53.22
$739.65K
David Alan Campbell
27 Sep 2024
President and CEO
Sold on a plan
795
$47.84
$38.03K
David Alan Campbell
27 Sep 2024
President and CEO
Sold on a plan
5,248
$46.86
$245.90K
David Alan Campbell
27 Sep 2024
President and CEO
Sold on a plan
18,957
$46.09
$873.71K
Thomas DiRaimondo
27 Sep 2024
Chief Scientific Officer
Sold on a plan
675
$47.22
$31.88K
Thomas DiRaimondo
27 Sep 2024
Chief Scientific Officer
Sold on a plan
4,325
$46.21
$199.84K

What was left out

Form 4 filings counted 136
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 22
Sales on a Rule 10b5-1 plan 12
Sales straight out of an exercise 31
Sales at will 60
Transactions with no price 0
Shares from compensation/vesting 36,004,274
Sales filed before the plan box existed 12
History held since 14 Jun 2021